Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors

What This Trial Is About

Researchers are studying the safety, feasibility, and diagnostic ability of a new PET imaging tracer called 68Ga-SorB. This tracer targets Sortilin, a receptor found in various solid tumors such as melanoma, liver, lung, pancreatic, breast, ovarian cancers, and cholangiocarcinoma. The study is exploratory and aims to compare this new imaging method with the standard 18F-FDG PETCT to improve tumor detection and diagnosis. Participants will receive a single intravenous dose of 68Ga-SorB followed by a whole-body PETCT scan about 60 minutes later. The imaging results will be compared with those from standard 18F-FDG PETCT scans performed around the same time. No treatment is given as part of this study it focuses solely on diagnostic imaging. Researchers will assess safety, tracer distribution in the body, tumor uptake, and how well the new tracer detects tumors compared to standard imaging. During the study, participants will undergo 68Ga-SorB PETCT imaging and may have clinically indicated 18F-FDG PETCT scans. Safety will be monitored from tracer administration until about 24 hours after imaging. Researchers will evaluate tumor uptake using standardized uptake values and compare lesion detection rates between the two imaging methods. Follow-up via pathology or clinical evaluation will help confirm diagnostic accuracy. The total study period includes imaging visits and follow-up assessments up to approximately three months.

68Ga-SorB PET/CT Imaging in Patients With Solid Tumors